No way found to predict PML cases with MS drug Tysabri
This article was originally published in Scrip
Executive Summary
There is no way to predict which MS patients receiving Biogen Idec/Elan's monoclonal antibody, Tysabri (natalizumab),will develop progressive multifocal leucoencephalopathy (PML), the potentially-fatal rare brain infection that has been associated with the therapy, according to a recent analysis conducted by Biogen Idec.